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Abstract
Background: Pulmonary surfactant D (SP-D) has important regulatory functions for innate immunity and has been
implicated as a biomarker for chronic obstructive pulmonary disease (COPD). We hypothesized that COPD patients
would have reduced bronchoalveolar lavage (BAL) fluid SP-D levels compared to healthy smoking and non-
smoking controls.
Methods: BAL SP-D and phospholipids were quantified and corrected for dilution in 110 subjects (65 healthy
never smokers, 23 smokers with normal spirometry, and 22 smokers with COPD).
Results: BAL SP-D was highest in never smokers (mean 51.9 μg/mL ± 7.1 μg/mL standard error) compared to both
smokers with normal spirometry (16.0 μg/mL ± 11.8 μg/mL) and subjects with COPD (19.1 μg/mL ± 12.9 μg/mL;
P < 0.0001). Among smokers with COPD, BAL SP-D correlated significantly with FEV1% predicted (R = 0.43; P < 0.05);
however, the strongest predictor of BAL SP-D was smoking status. BAL SP-D levels were lowest in current smokers (12.8
μg/mL ± 11.0 μg/mL), intermediate in former smokers (25.2 μg/mL ± 14.2 μg/mL; P < 0.008), and highest in never
smokers. BAL phospholipids were also lowest in current smokers (6.5 nmol ± 1.5 nmol), intermediate in former smokers
(13.1 nmol ± 2.1 nmol), and highest in never smokers (14.8 nmol ± 1.1 nmol; P < 0.0001).
Conclusions: These data suggest that smokers, and especially current smokers, exhibit significantly reduced BAL
SP-D and phospholipids compared to nonsmokers. Our findings may help better explain the mechanism that leads
to the rapid progression of disease and increased incidence of infection in smokers.
Background
Chronic obstructive pulmonary disease (COPD) is the
fourth leading cause of death in the United States [1],
and worldwide, both COPD morbidity and mortality are
expected to increase dramatically in the next ten years.
Cigarette smoke is the major risk factor for COPD; how-
ever, not all smokers are diagnosed with COPD. One
possible explanation for why some smokers do not
develop clinically important COPD is the role that host
factors play in limiting damage from smoking. One of the
limitations in COPD research has been a lack of lung-
specific biomarkers, particularly ones that could play a
role in both pathogenesis and therapy. Surfactant protein
D (SP-D) is a strong candidate for such a biomarker [2].
SP-D is a large multimeric, calcium binding glycopro-
tein that is a member of the collectin family. The pro-
tein serves as an innate immune regulatory molecule
and is produced predominantly in the lungs. SP-D pro-
motes the elimination of pathogens by its ability to
recognize carbohydrate structures on the surface of
large numbers of bacteria, viruses and fungi. Both envir-
onmental and genetic factors have been shown to con-
tribute to SP-D expression [3].
Currently there are conflicting data regarding the role
of SP-D in the pathogenesis of COPD. Some polymorph-
isms in the SP-D gene have been associated with COPD
[4,5]; however, replication studies have not confirmed
these findings [6]. Serum levels of SP-D have been
reported to be higher in COPD patients [7], and those
w i t hh i g hs e r u mS P - Dh a v em o r eC O P De x a c e r b a t i o n s
[8], but other reports have found that SP-D is not
affected by smoking status [9]. The use of SP-D as a
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that found regular inhalation of salmeterol and flutica-
sone lowers serum SP-D levels in COPD patients [10].
Although SP-D is predominantly a lung protein, there
are very few studies that have reported lung SP-D in
smokers. Hirama et al. reported that smoking increases
SP-D lung mRNA expression and protein in bronchoal-
veolar lavage (BAL) in a mouse smoking model [11]. In
contrast, human studies have reported that smokers
have lower BAL SP-D compared to non-smokers
[12,13]. These data suggest that SP-D could be a good
biomarker for COPD and that smoking may alter SP-D
levels in the lung; however, most of these studies were
limited by small sample size, lack of inclusion of a
group of former smokers, no description of lung func-
tion, lack of correction for dilution during the BAL pro-
cedure, and no measurement of total phospholipids. In
this study, we overcame size limitations by evaluating a
larger study group of 110 subjects, including former
smokers. Additionally, we performed spirometry and
corrected BAL SP-D by measuring dilution of plasma to
BAL urea as well as total phospholipids. The goals of
t h i ss t u d yw e r et oe x a m i n eS P - Da n dp h o s p h o l i p i d
levels in normal nonsmokers as well as current and for-
mer smokers with and without COPD to determine
whether significant changes are associated with smoke
exposure and COPD.
Methods
Subjects
All subjects were studied under protocols approved by
the Institutional Review Board at National Jewish Health
(HS-1725) with guidelines recommended by the
National Institutes of Health. Written informed consent
was obtained for all subjects. Subjects were free of sig-
nificant chronic disease (other than COPD) that might
put them at risk during bronchoscopy (e.g. known con-
gestive heart failure, MI in past year, history of pneumo-
nia in the past 6 months, or bronchitis/COPD
exacerbation within the past month) and recruited from
the community by word of mouth and written advertise-
ments. Subjects were excluded if they had a history of
lung cancer within or were suspected of having lung
cancer after their bronchoscopy. A total of 110 subjects
were recruited in Denver, Colorado. Smokers were
defined as having smoked at least 10 pack years. Never
smokers were defined as having smoked less than 100
cigarettes over their lifetime. Smokers were self-defined
as being current smokers or former smokers with a quit
date of at least one month prior to bronchoscopy. Cur-
rent smokers had their last cigarette a mean of 2.1
hours prior to bronchoscopy (range: 1 - 3 hours). Post
bronchodilator spirometry and the diagnosis of COPD
were made using Global initiative for chronic
Obstructive Lung Disease (GOLD) criteria [14]. The
percent predicted FEV1 represents the maximum
volume of air expired one second after the onset of full
expiration compared to that predicted for one’s age, sex,
height, and race. Among the COPD group there were 6
categorized as GOLD 1, 8 categorized GOLD 2, 4 cate-
gorized as GOLD 3, and 4 categorized as GOLD 4.
Comorbidities of more than 3% in the population
included: diabetes (N = 5); hypercholesterolemia
(N = 8); hypertension (N = 12); and a remote history of
pneumonia (N = 9). 101 subjects self-reported as non-
Hispanic (92 White, 8 black, and 1 more than one race),
5 subjects self reported as Hispanic (5 White now classi-
fied as American Indian), and 3 had unreported race
and ethnicity. Active inhaled corticosteroid use was 6/22
in COPD subjects, 1/23 smokers without COPD, and
none of the non-smoking controls. None of the non-
smoking controls and only 7/22 COPD subjects and 2/
23 smoking controls reported a history of exacerbations
within the past year.
BAL and Blood Collection
Six mL of blood was withdrawn from the antecubital
vein into a sterile 13 × 100 mm sodium heparin Vacu-
tainer Plus (BD, New Jersey). The sample was immedi-
ately centrifuged at 2100 × g for 10 minutes at room
temperature and then cell free aliquots were frozen at
-80°C. BAL fluid was obtained from a 60 ml saline
lavage with the bronchoscope wedged in the anterior
segment of the right upper lobe. Samples were centri-
fuged at 1500 × g for 10 minutes at 4°C to remove cells
and cellular debris and the supernatant was immediately
frozen at -80°C. All reagents were supplied by Sigma
Chemical (St. Louis, MO) unless otherwise noted.
Determination of SP-D in BAL
Human SP-D was measured by sandwich enzyme-linked
immunosorbent assay (ELISA) using polyclonal human
SP-D antibodies developed in rabbit. SP-D was detected
using anti-human SP-D IgG and a horseradish peroxi-
dase (HRP) conjugated secondary antibody. Standards
contained recombinant human SP-D protein produced
in Chinese hamster ovary (CHO) cells as previously
described [15]. Standards ranged from 40 ng/mL to
0.625 ng/mL. BAL samples were diluted serially in ratios
ranging from 1:5 to 1:40 in buffer containing 3% non-fat
dry milk in phosphate buffered saline (PBS) with 1%
Trition X-100. The samples were quantified by light
absorbance at 405 nm approximately 40 minutes after
addition of developer. The developer used was the Invi-
trogen (Carlsbad, CA) ABTS Chromogen/Substrate
Solution for ELISA. Each sample was measured in tripli-
cate and the values averaged. The coefficient of variation
(CFV%) of absorbance among triplicate samples was
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sample was retested if the CFV% (absorbance) of its
BAL SP-D measurement exceeded 13.63%.
Determination of Phospholipids
Lipids were extracted from a 1 mL sample of BAL by the
method of Bligh and Dyer [16]. Lipid phosphorus was
determined by the method of Rouser [17]. The samples
were quantified by light absorbance at 820 nm with a stan-
dard curve ranging from 1 to 35 nmol sodium phosphate.
Determination of Blood Urea
Blood urea nitrogen (BUN) was measured using the
Stanbio Laboratory (Boerne, TX) Urea Nitrogen (BUN)
Liqui-UV Procedure No. 2020 Kit. The blood samples
were diluted two-fold with 5 μL of ultra pure distilled
water. In addition to the diluted sample, 200 μL of BUN
reagent was added to a 96-well microtiter plate. The
samples were quantified by light absorbance at 340 nm,
5 minutes after the BUN reagent was added. Urea stan-
dards ranged from 0.469 to 30 mg/dL. Each assay was
preformed in triplicate. Final urea concentrations were
recorded as the average of the three triplicate samples.
Statistical Analysis
SP-D levels were natural log transformed to better
approximate model assumptions in all cases. SAS ver-
sion 9.2 and JMP version 8.0 for Macintosh (SAS Insti-
tute, Cary, NC) was used to compute means and
standard deviations. In the primary analysis, SP-D levels
were corrected for BAL dilution by multiplying mea-
sured values by each sample’s dilution factor (BUN/BAL
urea nitrogen). The mean dilution factor was 85.0 ±
72.1 (range: 11.5 to 499.5), and there were no differ-
ences in dilution factor among groups. In secondary
analysis, BAL SP-D was expressed per nanomole of lipid
phosphate. Means were compared by ANOVA. A signif-
icant P value was considered to be <0.05. Linear regres-
sion was used for continuous variables (including: sex,
age, pack years, FEV1 and FVC).
Results
Demographics including age, sex, pack years, and lung
function sorted by smoking history of the 110 subjects
participating in this study are listed in Table 1. Addi-
tional demographic data included: BMI (mean 26, stan-
dard deviation 3.6) and years smoked (mean 37 years,
standard deviation 10.6 years). The distribution of men
and women was not significantly different among
groups, but the never smokers were younger than both
the smokers with and without COPD (P < 0.001). Of
the smokers, those with COPD were also significantly
older than those without COPD (P < 0.001). Smokers
with COPD were more likely to be former smokers
compared to smokers without COPD (P < 0.05) and
also had higher reported pack years (P < 0.01). By defi-
nition, the smokers with COPD had worse lung function
compared to the never smoker and smoker control
group. Because of the potential effects of current smok-
ing on SP-D and phospholipid levels, we also analyzed
the smoker groups based on whether they were current
or former smokers. Current smokers were younger
(56 ± 8 years) compared to former smokers (63 ± 8
years; P < 0.05). Current smokers also had slightly better
lung function compared to former smokers (FEV1%
predicted 83% ± 21% versus 64% ± 30%; P < 0.05). How-
ever, there were no significant differences in pack years
smoking between current (43 ± 22 pack years) and for-
mer smokers (56 ± 29 pack years).
Compared to smokers with or without COPD, the
never smoker group had significantly higher recovered
(natural log transformed) BAL SP-D with (Figure 1 and
Additional File 1: Supplemental Figure S1) and without
(Figure 2 and Additional File 1: Supplemental Figure S2)
correction for dilution by urea (Table 2 and Additional
File 1: Supplemental Table S1). BAL recovered phospho-
lipids were also significantly higher in the never smokers
compared to the smoker groups (Figure 3 and Addi-
tional File 1: Supplemental Figure S3). When SP-D was
corrected for phospholipids, t h ed i f f e r e n c eb e t w e e nt h e
never smokers and the smokers was not significant (Fig-
ure 4 and Additional File 1: Supplemental Figure S4).
Although the non-smokers were younger than smokers,
there were no significant correlations between age and
SP-D in the non-smokers. There were no statistically
significant associations between surfactant or phospholi-
pids and other demographic variables such as comorbid-
ities, BMI, years smoked, race or ethnicity, active
inhaled corticosteroid use, or a history of exacerbations.
There were no statistically significant differences in
SP-D (corrected or uncorrected) or phospholipid levels
between the smokers with COPD and the smokers with-
out COPD (Table 2 and Additional File 1: Supplemental
Table S1); however, there was a correlation between
FEV1% predicted and recovered BAL SP-D (R = 0.43;
P < 0.05) among COPD subjects. Compared to former
smokers, current smokers had significantly less BAL
phospholipids (6.5 ± 1.4 versus 13.3 ± 2.0 nmol/ml; P =
0.0088; Additional File 1: Supplemental Figure S3). Cur-
rent smokers also had lower SP-D compared to the for-
mer smokers (13 ± 17 versus 25 ± 21 μg/ml corrected
for dilution; P = 0.016). In a multiple regression model
that included age, FEV1% predicted, and smoking his-
tory, smoking status (current or former) was a signifi-
cant predictor for BAL SP-D (P < 0.05) and
phospholipids (P < 0.001).
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The main finding of this study was that current smoking
was associated with lower levels of BAL SP-D and phos-
pholipids compared to former and never smokers.
Although we did not find a statistical difference in the
BAL SP-D or phospholipids levels between COPD patients
and smokers without COPD, lower BAL SP-D was asso-
ciated with worse lung function in COPD subjects. A likely
explanation for why smokers without COPD did not have
significantly higher SP-D and phospholipids compared to
COPD subjects is that there were significantly more cur-
rent smokers in the control group compared to the COPD
group. The multiple regression analysis suggested that cur-
rent smoking was the strongest predictor of diminished
BAL SP-D and phospholipid levels.
The first study of the effect of smoking on phospholi-
pids was reported by Finley and Ladman [18], who
noted lower BAL return of phospholipids in smokers.
Interestingly they noted that three of the smokers who
quit had a rapid rise in BAL phospholipids after as little
as one month. The earliest study to document the
effects of smoking on human BAL SP-D was a small
study of 8 smokers and 12 nonsmokers by Honda et al
[13]. These investigators reported similar results to us in
that current smokers had lower BAL SP-D and phos-
pholipids compared to never smokers. Unlike our study,
the investigators did not study former smokers nor did
they report on lung function or age of subjects; however,
similar to us, they did find that correcting surfactant
protein levels for phospholipid content made differences
Table 1 Demographics of study participants
Never Smoker (N = 65) Smokers (N = 45)
Control (N = 23) COPD (N = 22)
Age 28 ± 8 53 ± 5 64 ± 9
Sex (m/f) 36/29 18/5 14/8
Current Smokers 0% 78% 41%
Pack Years 0 36 ± 14 60 ± 29
FEV1 post bronchodilator (l) 4.2 ± 0.9 3.2 ± 0.7 1.7 ± 0.7
FEV1 (% predicted) 103% ± 11% 95% ± 13% 56% ± 21%
FEV1/FVC 0.85 ± 0.06 0.79 ± 0.05 0.53 ± 0.12
Shown are means ± standard deviations; P values in text.
Figure 1 Bronchoalveolar lavage fluid SP-D levels in never, former, and current smokers with normal lung function or COPD as
defined by spirometery. The never smokers had significantly higher SP-D levels in their lavage fluid compared to former and current smokers.
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findings are also consistent with Betsuyaku et al [12]
who reported BAL SP-D in 22 nonsmokers and 82 smo-
kers. The subjects in this stu d yw e r ea l m o s te x c l u s i v e l y
males and investigators did not correct for dilution nor
did they report total phospholipid content. They also
found that SP-D did not change with age alone, how-
ever, it was decreased in middle- aged or elderly smo-
kers when compared with similarly aged nonsmokers.
Although we did not measure serum SP-D, several
investigators have found a different relationship between
serum surfactant proteins in smokers and COPD
patients. In a study of 237 healthy smoking and non-
smoking subjects, serum levels of SP-A were signifi-
cantly higher in male smokers compared to male
nonsmokers [19]. There was a non-significant trend for
lower SP-A values in young nonsmoking males and
females compared to older subjects. Mutti et al [7]
found that active smokers and COPD subjects had
higher SP-D serum levels compared to control never
smokers; however, there was no correlation with GOLD
stage nor were there reports of the effect of age on SP-
D levels. The reason for the opposite relationship
between BAL and blood SP-D is unclear. Sin et al has
proposed that the lower levels of BAL SP-D may be due
to increased transmigration of SP-D from the alveolar
space into blood [2]. There are, however, few data to
support this theory. Genetic studies of twins have sug-
gested that serum SP-D levels are influenced by a com-
bination of environmental effects (e
2 = 0.19), additive
genetic effects (h
2 = 0.42), and the effect of a single
nucleotide polymorphism (Met11Thr) (q
2 = 0.39) [3].
None of the BAL studies have reported genotyping of
the SP-D gene; however, a large replication genetic
Figure 2 Bronchoalveolar lavage fluid SP-D levels corrected for dilution in never, former, and current smokers with normal lung
function or COPD as defined by spirometry. The dilution factor of the BAL was calculated by the ratio of plasma/BAL urea. The never
smokers had significantly higher SP-D levels in their lavage fluid compared to former and current smokers.
Table 2 Bronchoalveolar lavage fluid SP-D and phospholipids
Never Smoker Smokers
Control COPD P
BAL SP-D (uncorrected) ng/ml 558 ± 309 287 ± 204 235 ± 203 <0.0001
BAL SP-D (corrected) μg/ml 51.9 ± 64.3 16.0 ± 19.3 19.1 ± 20.5 <0.0001
BAL phospholipid (nmol/ml) 14.8 ± 7.4 8.9 ± 7.8 8.5 ± 7.7 <0.0001
BAL SP-D ng/phospholipid nmol 42.2 ± 31.5 52.1 ± 61.8 44.8 ± 33.3 N.S.
Shown are means ± standard deviations; P values were calculated using ln transformed data (see Additional File 1: Supplemental Table S1).
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Page 5 of 8Figure 3 Bronchoalveolar lavage fluid phospholipid levels in never, former, and current smokers with normal lung function or COPD
as defined by spirometry. Lipids were extracted and phospholipids measured. The never smokers had significantly more phospholipids in their
lavage fluid compared to former and current smokers. Current smokers had significantly lower levels compared to former smokers.
Figure 4 Bronchoalveolar lavage fluid SP-D corrected for total phospholipid in never, former, and current smokers with normal lung
function or COPD as defined by spirometry. There were no significant differences among groups.
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COPD [6].
Animal studies have shed some light on the role of
SP-D in smoking and the effects of aging, but may be
difficult to extrapolate to humans. Hirama et al [11]
found that mice exposed to cigarette smoke for six
months had increased lung SP-D mRNA expression and
increased BAL SP-D protein in the lungs. Furthermore
over-expression of SP-D in A549 cells was found to
increase survival in vitro after exposure to 4% cigarette
smoke extract. Reanalysis of SP-D gene expression from
normal lung (NCBI GEO database accession #GSE1643
[20]) revealed no differences in SP-D gene expression
among healthy never smokers, current smokers or non-
smokers; however, there was a significant negative cor-
relation to age (Spearman’s rho = -0.60995, P = 0.003).
Thus animal models, which showed increased SP-D
gene expression after smoke exposure, and human gene
expression studies, which show no difference in gene
expression by smoking status, contrast with human
SP-D protein quantification studies that have consis-
tently found decreased BAL SP-D protein in smokers.
The reasons for the differences between the mouse
model and human gene expression studies are unclear,
but suggest that lower levels of protein in the BAL of
human smokers might be the result of increased clear-
ance or increased degradation.
SP-D is recognized as an important regulator of innate
immunity capable of binding pathogens and facilitating
phagocytosis [21]. The protein also exerts direct micro-
bicidal activity on selected bacteria and fungi [22,23].
Lower levels of SP-D caused by cigarette smoking may
thus weaken lung immunity. Mice harboring SP-D null
alleles show reduced bacterial clearance and elevated
basal levels of inflammation [24,25]. In vitro SP-D can
suppress inflammatory responses elicited by LPS and
peptidogylcan [26,27]. Thus, chronically reduced levels
of SP-D are expected to cause defects in microbial
recognition and impaired suppression of inflammation.
Cigarette smoking as has other strong effects on innate
immunity of the lung independent of surfactants and
phospholipids [28]. These effects include impairment of
T-cell function leading to susceptibility of infection, dys-
functional ciliary epithelium, and reduction of macro-
phage and neutrophils phagocytic capabilities.
Recent evidence also implicates anionic pulmonary
surfactant phospholipids as important negative regula-
tors of TLR4 activation and inflammation as well as
respiratory syncytial virus induced inflammation [29,30].
Thus, reduction of both SP-D and surfactant phospholi-
pids in smokers is likely to increase inflammation and
predispose these individuals to certain viral infections.
There are several limitations of this and previous stu-
dies. Foremost is that the mechanisms by which
smoking is associated with lower recovered BAL SP-D
and phospholipids is unknown. Schmekel et al have pos-
tulated that alveolar macrophages in smokers may
increase clearance of phospholipids [31] or alternatively
there could be more leakage of surfactant proteins and
lipids into blood [2,18]. Another possible explanation
for our observed differences in BAL phospholipids is the
younger age of controls; however, the correlation
between BAL phospholipids and age has only been
demonstrated in children < 8 years of age [32], which is
consistent with our inability to demonstrate a relation-
ship between aging and phospholipids or SP-D levels in
our adult never smokers. Nevertheless, both an age and
a smoking-related decrease in SP-D and phospholipids
might explain why COPD is predominantly a disease of
elderly smokers. Furthermore, because current smokers
were allowed their last cigarette two hours prior to the
collection of BAL, the unknown acute effects of smoking
on SP-D and phospholipids may have impacted our
results. Finally, in this study, the relationship between
COPD and BAL SP-D was probably understated because
there were significantly more current smokers in the
smokers with normal lung function group, compared to
smokers with COPD.
Conclusion
In this study we demonstrate that smoking, especially
current smoking, and worse lung function are associated
with low BAL SP-D and phospholipid levels. Reduced
phospholipids and surfactant proteins may predispose
smokers to infections or defective suppression of inflam-
mation in response to pathogen exposure, ambient LPS
levels, or LPS that can be found in cigarette smoke.
This may lead to a more rapid decline in lung function
than is normally associated with aging.
Additional material
Additional file 1: Natural log transformed data used for analysis.A
table summarizing natural log transformed data and four figures showing
the distribution of natural log transformed data by group
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